Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms

Endocrine-Related Cancer

Volumn 22, Issue 5, 2015, Pages 805-818

  Centenera, Margaret M ^a,b   Carter, Sarah L ^a   Gillis, Joanna L ^a,b   Marrocco Tallarigo, Deborah L ^a   Grose, Randall H ^b   Tilley, Wayne D ^a   Butler, Lisa M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Androgen receptor; Combination; Heat shock protein; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR V7; BICALUTAMIDE; CASPASE; ENZALUTAMIDE; HEAT SHOCK PROTEIN 90; LUMINESPIB; TANESPIMYCIN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR ANTAGONIST; ANILIDE; AR PROTEIN, HUMAN; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; MESSENGER RNA; NITRILE; TOLUENESULFONIC ACID DERIVATIVE; TUMOR MARKER;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AND RELATED PHENOMENA; C4 2B CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN; CHROMATIN BINDING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEAT SHOCK RESPONSE; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; MONOTHERAPY; PC 3 CELL LINE; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; APOPTOSIS; BENZOQUINONES; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION PROFILING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LACTAMS, MACROCYCLIC; MALE; NITRILES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOSYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 84942083466     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0541     Document Type: Article

References (67)

1. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW & Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of the National Cancer Institute 91 1869-1876. (doi:10.1093/jnci/91.21.1869)
2. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL et al. 2014 AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine 371 1028-1038. (doi:10.1056/NEJMoa1315815)
3. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ & Whitesell L 2000 Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clinical Cancer Research 6 3312-3318.
4. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, CampbellMet al. 2005 Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. Journal of Clinical Oncology 23 4152-4161. (doi:10.1200/JCO.2005.00.612)
5. Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological) 57 289-300.
6. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR & TilleyWD 2001 Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research 7 1273-1281.
7. Cai C & Balk SP 2011 Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocrine-Related Cancer 18 R175-R182. (doi:10.1530/ERC-10-0339)
8. Centenera MM, Gillis JL, Hanson A, Jindal S, Taylor RA, Risbridger G, Sutherland PD, Scher HI, Raj GV, Knudsen KE et al. 2012 Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research 18 3562-3570. (doi:10.1158/1078-0432.CCR-12-0782)
9. Centenera MM, Fitzpatrick AK, Tilley WD & Butler LM 2013 Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta 1835 211-218.
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
11. Chen Y, Sawyers CL & Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology 8 440-448. (doi:10.1016/j.coph.2008.07.005)
12. Chou TC & Talalay P 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22 27-55.
13. Conde R, Belak ZR, Nair M, O'Carroll RF & Ovsenek N 2009 Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochemistry and Cell Biology 87 845-851. (doi:10.1139/O09-049)
14. DehmSM, Schmidt LJ,HeemersHV, Vessella RL & Tindall DJ 2008 Splicing of anovelandrogenreceptor exongenerates a constitutively activeandrogen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
15. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F et al. 2008 NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Research 68 2850-2860. (doi:10.1158/0008-5472.CAN-07-5256)
16. Eisen MB, Spellman PT, Brown PO & Botstein D 1998 Cluster analysis and display of genome-wide expression patterns. PNAS 95 14863-14868. (doi:10.1073/pnas.95.25.14863)
17. Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI & Sgouros G 2003 Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supraadditive growth suppression in human prostate carcinoma spheroids. Cancer Research 63 8393-8399.
18. Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA et al. 2011 Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 11 468. (doi:10.1186/1471-2407-11-468)
19. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME & Nelson CC 2004 Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research 64 2212-2221. (doi:10.1158/0008-5472.CAN-2148-2)
20. Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D et al. 2013 Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biology & Therapy 14 347-356. (doi:10.4161/cbt.23626)
21. Georget V, Terouanne B, Nicolas JC & Sultan C 2002 Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41 11824-11831. (doi:10.1021/bi0259150)
22. Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD & Butler LM 2013 Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget 4 691-704.
23. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG et al. 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 2305-2313. (doi:10.1158/0008-5472.CAN-08-3795)
24. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y et al. 2013 Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. International Journal of Oncology 42 35-43.
25. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP et al. 2008 A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormonerefractory metastatic prostate cancer. Clinical Cancer Research 14 7940-7946. (doi:10.1158/1078-0432.CCR-08-0221)
26. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E et al. 2012 Distinct transcriptional programsmediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research 72 3457-3462. (doi:10.1158/0008-5472.CAN-11-3892)
27. Huang da W, Sherman BT & Lempicki RA 2009 Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4 44-57. (doi:10.1038/nprot.2008.211)
28. Iyer G,Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q et al. 2012 A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology 69 1089-1097. (doi:10.1007/s00280-011-1789-3)
29. Izar B, Rotow J, Gainor J, Clark J & Chabner B 2013 Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. Pharmacological Reviews 65 1351-1395. (doi:10.1124/pr.113.007807)
30. Karantanos T, Corn PG & Thompson TC 2013 Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32 5501-5511. (doi:10.1038/onc.2013.206)
31. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E et al. 2003 Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research 9 3578-3588.
32. Knudsen KE, Arden KC & Cavenee WK 1998 Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. Journal of Biological Chemistry 273 20213-20222. (doi:10.1074/jbc.273.32.20213)
33. Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L & Pili R 2014 Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PLoS ONE 9 e103680. (doi:10.1371/journal.pone.0103680)
34. Kuil CW, Berrevoets CA & Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. Journal of Biological Chemistry 270 27569-27576. (doi:10.1074/jbc.270.46.27569)
35. Labrie F 2011 Blockade of testicular and adrenal androgens in prostate cancer treatment. Nature Reviews. Urology 8 73-85. (doi:10.1038/nrurol. 2010.231)
36. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH & Dehm SM 2011 Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research 71 2108-2117. (doi:10.1158/0008-5472.CAN-10-1998)
37. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA & Dehm SM 2013 Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research 73 483-489. (doi:10.1158/0008-5472.CAN-12-3630)
38. Lu X, Xiao L, Wang L & Ruden DM 2012 Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochemical Pharmacology 83 995-1004. (doi:10.1016/j.bcp.2011.11.011)
39. Masiello D, Cheng S, Bubley GJ, Lu ML & Balk SP 2002 Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. Journal of Biological Chemistry 277 26321-26326. (doi:10.1074/jbc.M203310200)
40. Maughan BL & Antonarakis ES 2015 Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opinion on Pharmacotherapy 16 1521-1537. (doi:10.1517/14656566.2015. 1055249)
41. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP & Gao AC 2013 NF-kB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Molecular Cancer Therapeutics 12 1629-1637. (doi:10.1158/1535-7163.MCT-13-0027)
42. Ochel HJ & Gademann G 2006 In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation. Anticancer Research 26 2085-2091.
43. Pratt WB & Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews 18 306-360.
44. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP & Belani CP 2010 Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heatshock protein 90, in patients with advanced solid tumors. Journal of Clinical Oncology 28 1520-1526. (doi:10.1200/JCO.2009.25.0415)
45. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al. 2015 Integrative clinical genomics of advanced prostate cancer. Cell 161 1215-1228. (doi:10.1016/j.cell.2015.05.001)
46. Rossi S, Graner E, Febbo P,Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S & Loda M 2003 Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Molecular Cancer Research 1 707-715.
47. Samuel TA, Sessa C, Britten C, Milligan KS, Mita MM, Banerji U, Pluard TJ, Stiegler P, Quadt C & Shapiro G 2010 AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. ASCO Meeting Abstracts 28 2528.
48. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J et al. 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375 1437-1446. (doi:10.1016/S0140-6736(10)0172-9)
49. Schiewer MJ, Augello MA & Knudsen KE 2012 The AR dependent cell cycle: mechanisms and cancer relevance. Molecular and Cellular Endocrinology 352 34-45. (doi:10.1016/j.mce.2011.06.033)
50. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J & Odom DT 2009 ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48 240-248. (doi:10.1016/j.ymeth. 2009.03.001)
51. Shafi AA, Cox MB & Weigel NL 2013 Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78 548-554. (doi:10.1016/j.steroids.2012.12.013)
52. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB et al. 2002 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical Cancer Research 8 986-993.
53. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G et al. 2007 Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical Cancer Research 13 1775-1782. (doi:10.1158/1078-0432.CCR-06-1863)
54. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al. 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 120 2715-2730. (doi:10.1172/JCI41824)
55. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W & Verhoeven G 1996 Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137 4468-4474.
56. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W & Verhoeven G 2004 Androgens, lipogenesis and prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 92 273-279. (doi:10.1016/j.jsbmb.2004.10.013)
57. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
58. Trepel J, Mollapour M, Giaccone G & Neckers L 2010 Targeting the dynamic HSP90 complex in cancer. Nature Reviews. Cancer 10 537-549. (doi:10.1038/nrc2887)
59. Tyrrell CJ, Iversen P, Tammela T, Anderson J, Bjork T, Kaisary AV &Morris T 2006 Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International 98 563-572. (doi:10.1111/j.1464-410X.2006.06275.x)
60. Vanaja DK, Mitchell SH, Toft DO & Young CY 2002 Effect of geldanamycin on androgen receptor function and stability. Cell Stress & Chaperones 7 55-64. (doi:10.1379/1466-1268(2002)07!0055:EOGOARO2.0.CO;2)
61. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A & Speleman F 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3 RESEARCH0034. (doi:10.1186/gb-2002-3-7-research0034)
62. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA & Mulder E 1992 Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31 2393-2399. (doi:10.1021/bi00123a026)
63. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
64. Whitesell L, Bagatell R & Falsey R 2003 The stress response: implications for the clinical development of hsp90 inhibitors. Current Cancer Drug Targets 3 349-358. (doi:10.2174/1568009033481787)
65. Williams CR, Tabios R, Linehan WM & Neckers L 2007 Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. Journal of Urology 178 1528-1532. (doi:10.1016/j.juro.2007.05.120)
66. Workman P, Burrows F, Neckers L & Rosen N 2007 Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Annals of the New York Academy of Sciences 1113 202-216. (doi:10.1196/annals.1391.012)
67. Zou J, Guo Y, Guettouche T, Smith DF & Voellmy R 1998 Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94 471-480. (doi:10.1016/S0092-8674(00)1588-3)